<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="2-part\PMC6958466\results\search\tropicalVirus\results.xml">
  <result pre="Approaches for Surveillance, Drug Discovery, and Vaccine Design for the" exact="Zika" post="Virus BasakSubhash C.1*https://orcid.org/0000-0003-3529-7820MajumdarSubhabrata2†https://orcid.org/0000-0002-1649-7731NandyAshesh3RoyProyasha3DuttaTathagata3VrackoMarjan4BhattacharjeeApurba K.5[1], [2], subho@research.att.com[3], anandy43@yahoo.comproyasha.roy@gmail.comtathagata.dk@gmail.com[4], marjan.vracko@ki.si[5], ab3094@georgetown.edu"/>
  <result pre="emerge and reemerge at random. The recent outbreak of the" exact="Zika" post="virus (ZIKV) is one such menace that shook the"/>
  <result pre="and discuss how they can work together to proactively combat" exact="ZIKV" post="or future emerging pathogens. viral epidemics Zika virus (ZIKV)"/>
  <result pre="to proactively combat ZIKV or future emerging pathogens. viral epidemics" exact="Zika" post="virus (ZIKV) SIR models 2D graphical method peptide vaccine"/>
  <result pre="Of the Black Death 1. Discovery and Brief History The" exact="Zika" post="Virus (ZIKV) was first isolated in 1947 from a"/>
  <result pre="first isolated in 1947 from a rhesus monkey in the" exact="Zika" post="forest of Uganda [1]. In 1952, the virus was"/>
  <result pre="Africa and Asia at first. The first major outbreak of" exact="ZIKV" post="infection was reported from the Yap Island in the"/>
  <result pre="the origin and spread of ZIKV. Serosurvey of humans found" exact="ZIKV" post="throughout Africa, Asia, and Oceania. In 1954, there was"/>
  <result pre="there was a report of the first three cases of" exact="ZIKV" post="infection in humans in Oyo state, Nigeria [2]. In"/>
  <result pre="antibodies of ZIKV. The first direct evidence of the presence" exact="ZIKV" post="in the Asian continent and the first proof of"/>
  <result pre="stomach ache, anorexia, and dizziness [6]. Regarding the spread of" exact="ZIKV" post="from Africa to Asia, Liang et al. [7] put"/>
  <result pre="on mathematical modeling. These authors carried out quantitative analysis of" exact="ZIKV" post="evolution, nucleotide substitution rate, and the time to the"/>
  <result pre="their results these authors concluded that a &quot;global dissemination of" exact="ZIKV" post="spread was likely to have originated from Africa, followed"/>
  <result pre="as a possible portal of entry for the transmission of" exact="ZIKV" post="from Africa to south-eastern Asia during that wartime period.�?"/>
  <result pre="from Africa to south-eastern Asia during that wartime period.�? The" exact="Zika" post="virus attracted a heightened international attention following huge incidence"/>
  <result pre="the Latin Americas in 2015 [8]. Historically, the spread of" exact="ZIKV" post="happened in two phases [9]: (a) Cases of ZIKV"/>
  <result pre="of ZIKV happened in two phases [9]: (a) Cases of" exact="ZIKV" post="detected during the pre-epidemic period (1947 to 1999), and"/>
  <result pre="pre-epidemic period (1947 to 1999), and (b) case history of" exact="ZIKV" post="during 2007 to 2017, respectively. On 2 March 2015"/>
  <result pre="these states. All cases were mild, with no reported deaths." exact="Zika" post="was not suspected at that stage, and no tests"/>
  <result pre="was not suspected at that stage, and no tests for" exact="Zika" post="were carried out. On 1 February 2016, WHO [1]"/>
  <result pre="February 2016, WHO [1] declared that the recent association of" exact="Zika" post="infection with clusters of microcephaly and other neurological disorders"/>
  <result pre="subsequently in the November of 2016. 2. Virology 2.1. Structure" exact="ZIKV" post="is a member of the Flavivirus genus that is"/>
  <result pre="Flaviviridae family. Some important disease-causing viruses of this genus are" exact="Dengue" post="fever virus, Tick-borne encephalitis virus, West Nile virus, Japanese"/>
  <result pre="of this genus are Dengue fever virus, Tick-borne encephalitis virus," exact="West Nile" post="virus, Japanese encephalitis virus, and Zika virus [10]. These"/>
  <result pre="Tick-borne encephalitis virus, West Nile virus, Japanese encephalitis virus, and" exact="Zika" post="virus [10]. These viruses possess a single stranded positive"/>
  <result pre="5′-UTR and 3′-UTR regions [1,9,10,11]. The 3′ terminal end of" exact="ZIKV" post="has a sub-genomic Flavivirus RNA (sfRNA) region that is"/>
  <result pre="viral-host cell binding and membrane fusion during replication. Replication of" exact="ZIKV" post="occurs in the cytoplasm of infected cells [15,16]. After"/>
  <result pre="Evolution and Spread From its initial stage in Uganda, the" exact="ZIKV" post="has numerous alterations. Figure 2 gives a phylogenetic tree"/>
  <result pre="numerous alterations. Figure 2 gives a phylogenetic tree of 22" exact="ZIKV" post="sequences [17]. There are two major groups: one with"/>
  <result pre="was first detected in 1947, the pre-epidemics period of the" exact="Zika" post="virus spanned till 1999. Table 2 provides a brief"/>
  <result pre="country-wise details of infection. Following this, a summary of the" exact="ZIKV" post="epidemics, from 2007 to the present time, is given"/>
  <result pre="detailed list of information about the clinical aspects of the" exact="Zika" post="virus infection. A majority of people infected with Zika"/>
  <result pre="the Zika virus infection. A majority of people infected with" exact="Zika" post="virus do not develop too many overt symptoms. Typical"/>
  <result pre="do not develop too many overt symptoms. Typical symptoms of" exact="Zika" post="virus infection include mild fever, rash, joint/muscle pain, headache,"/>
  <result pre="Most people recover from these symptoms in around a week." exact="ZIKV" post="infection during pregnancy has been linked to several complications,"/>
  <result pre="to several complications, which are collectively referred to as congenital" exact="Zika" post="syndrome. These include miscarriage, severe microcephaly, and other fetal"/>
  <result pre="tissue damage in brain, eye damage [20,21]. Another complication of" exact="ZIKV" post="infection is its association with the Guillain–Barré syndrome (GBS),"/>
  <result pre="website gives the following information regarding the transmission of the" exact="ZIKV" post="transmission [24]. (a)Through mosquito bites: ZIKV is transmitted to"/>
  <result pre="the transmission of the ZIKV transmission [24]. (a)Through mosquito bites:" exact="ZIKV" post="is transmitted to people primarily through the bite of"/>
  <result pre="bites. (b)From mother to child: A pregnant woman can pass" exact="ZIKV" post="to her fetus during pregnancy. (c)Through sex: ZIKV can"/>
  <result pre="can pass ZIKV to her fetus during pregnancy. (c)Through sex:" exact="ZIKV" post="can be transmitted through sex from a person who"/>
  <result pre="can be transmitted through sex from a person who has" exact="Zika" post="to his or her partners. The virus can be"/>
  <result pre="the time. It can be passed from a person with" exact="Zika" post="before their symptoms start, while they have symptoms, and"/>
  <result pre="have symptoms, and after their symptoms end. This scenario of" exact="ZIKV" post="disease transmission is not without precedents in the human"/>
  <result pre="is a new disease! 4. Mathematical/Computational Analysis and Results in" exact="ZIKV" post="Virology, Peptide Vaccine Design, and Anti-Zika Drug Design Currently,"/>
  <result pre="of the above-mentioned multidisciplinary approach for the management of the" exact="ZIKV" post="issues. 4.1. Quantitative Epidemiological Modelling Strategies to Prevent Zika"/>
  <result pre="the ZIKV issues. 4.1. Quantitative Epidemiological Modelling Strategies to Prevent" exact="Zika" post="The major approaches of quantitative modelling for prevention and"/>
  <result pre="major approaches of quantitative modelling for prevention and mitigation of" exact="ZIKV" post="can be broadly categorized into two parts: mathematical models"/>
  <result pre="accurately predict future disease incidences. Data-driven modelling strategies for countering" exact="Zika" post="have been explored keeping a diverse types of end"/>
  <result pre="epidemiological modelling, [37] attempted to predict new primate reservoirs of" exact="ZIKV" post="in the wild based on their phenotypical characteristics. This"/>
  <result pre="spreads of the virus through proactive surveillance and prevention of" exact="ZIKV" post="spread from the at-risk primate species. A number of"/>
  <result pre="novel compounds that are inhibitors of different enzymes present in" exact="ZIKV" post="[38,39,40], as well as repurposing existing drugs used in"/>
  <result pre="as repurposing existing drugs used in treating diseases similar to" exact="Zika" post="[41]. A more detailed list of such in-silico methods"/>
  <result pre="later in this review. 4.2. Computer-Assisted Peptide Vaccine Design for" exact="Zika" post="Virus Vaccination is the most effective way to induce"/>
  <result pre="look at the current methods of vaccine development and particularly," exact="Zika" post="virus vaccines that hopefully might reach the market within"/>
  <result pre="in which two surface proteins are recombined with a weakened" exact="YFV" post="strain [47]. None exist for the Zika or Dengue"/>
  <result pre="with a weakened YFV strain [47]. None exist for the" exact="Zika" post="or Dengue viruses. An important point to note is"/>
  <result pre="weakened YFV strain [47]. None exist for the Zika or" exact="Dengue" post="viruses. An important point to note is that vaccines,"/>
  <result pre="II [48]. They are either DNA-based vaccines or inactivated whole" exact="Zika" post="virus (ZIKV) vaccines. Additionally, there are two recombinant viral"/>
  <result pre="with ZIKV. However, one of the challenges faced in administering" exact="Zika" post="vaccines is a naturally occurring phenomenon called antibody dependent"/>
  <result pre="dependent enhancement or ADE. Reportedly, in cases of a secondary" exact="Dengue" post="infection, it has been seen that the disease severity"/>
  <result pre="probable cause is an abnormal behavior of the antibodies against" exact="Dengue" post="virus—they aid in the virulence of this arbovirus resulting"/>
  <result pre="virus—they aid in the virulence of this arbovirus resulting in" exact="Dengue" post="Shock Syndrome or Dengue Hemorrhagic Fever [49]. Since Zika"/>
  <result pre="virulence of this arbovirus resulting in Dengue Shock Syndrome or" exact="Dengue" post="Hemorrhagic Fever [49]. Since Zika is closely related to"/>
  <result pre="in Dengue Shock Syndrome or Dengue Hemorrhagic Fever [49]. Since" exact="Zika" post="is closely related to Dengue, an individual with a"/>
  <result pre="Zika is closely related to Dengue, an individual with a" exact="Zika" post="vaccination might be severely affected by ADE if she"/>
  <result pre="she or he is subsequently or naturally infected with the" exact="Zika" post="virus. Despite the advancement of vaccine over the last"/>
  <result pre="every year incurring massive production and distribution costs. Hypothetically, a" exact="Zika" post="virus would mutate at the rate of 0.12–0.25% [50]"/>
  <result pre="the capsid, envelope, NS2A, NS3, NS4B, and NS5 proteins of" exact="Zika" post="virus [51,52,53,54,55,56]. Addressing the issue of ADE, Dos Santos"/>
  <result pre="response by constructing a NS5-based peptide vaccines that targets both" exact="Zika" post="as well as Dengue viruses. Furthermore, Richner et al."/>
  <result pre="NS5-based peptide vaccines that targets both Zika as well as" exact="Dengue" post="viruses. Furthermore, Richner et al. (2017) [58] assembled modified"/>
  <result pre="Richner et al. (2017) [58] assembled modified prME mRNA of" exact="Zika" post="virus in lipid nanoparticles. The genetic modification allowed for"/>
  <result pre="VP7 surface glycoprotein and for more than 200 sequences of" exact="HPV" post="L1 capsid protein [61]. Subsequently, the conserved peptide regions"/>
  <result pre="al. (2017) [62] were able to identify and characterize four" exact="Zika" post="virus epitopes in the envelope protein for an effective"/>
  <result pre="AI may not be too far a goal [66]. The" exact="Zika" post="virus pandemic has eased considerably after the sudden eruption"/>
  <result pre="Principle and Alignment Free Sequence Descriptors in the Characterization of" exact="ZIKV" post="Sequences &quot;All cases are unique and very similar to"/>
  <result pre="The Cocktail Party As indicated in Section 1 above [1,9,17,27]," exact="Zika" post="virus is an evolving pathogen undergoing numerous changes during"/>
  <result pre="and gain new insights. For the comparison of sequences of" exact="ZIKV" post="we have used two classes of descriptors based on"/>
  <result pre="distribution in the sequence. Thus, a graphical representation of the" exact="Zika" post="virus whole genome sequence would look like the one"/>
  <result pre="gives an overview of the base distributions along the whole" exact="Zika" post="virus genome. It shows that while the structural genes"/>
  <result pre="the sequence. Table 4 shows the gR values of the" exact="Zika" post="virus genomic sequences in Africa, Asia, and South America"/>
  <result pre="more set and compact with time. A phylogenetic tree of" exact="Zika" post="virus sequences (Figure 2) also shows clear separation between"/>
  <result pre="the application are given in [78]. Clustering and Analysis of" exact="ZIKV" post="Sequences Clustering (grouping) and classification (categorization) of objects are"/>
  <result pre="areas of the globe (Africa, Asia, South America). Comparison of" exact="ZIKV" post="sequesters using calculated sequence descriptors follows the sequence (structure)-property"/>
  <result pre="PCA- and SOM-based clustering analysis using the orthogonal descriptors for" exact="ZIKV" post="sequences [81]. For PCA and SOM calculations, the standard"/>
  <result pre="[82]. The data set consists of 310 genome sequences of" exact="ZIKV" post="hosted in different species (83% in Homo sapiens, 17%"/>
  <result pre="inaccurate, and brilliant. Together they are powerful beyond imagination.�?Albert Einstein" exact="ZIKV" post="is a flavivirus family of infection transmitted by mosquitos."/>
  <result pre="concern for the infection heightened because of babies born from" exact="ZIKV" post="infected mothers showed microcephaly and neurological complications [84]. Since"/>
  <result pre="pharmacophores�?. Although no anti-Zika drug is currently available, several promising" exact="ZIKV" post="drug targets have been reported in recent years [90]."/>
  <result pre="[90]. These targets with compounds have shown potent activity against" exact="ZIKV" post="and its proteins. Non-structural (NS) flavivirus proteins are believed"/>
  <result pre="both replication and virion maturation [91]. Crystallographic structures of several" exact="ZIKV" post="related NS proteins are now available from protein structural"/>
  <result pre="and therapeutic antibodies have been identified and developed having anti-" exact="ZIKV" post="activity. However, most of these studies were in vitro"/>
  <result pre="nine vaccines reached phase I or II clinical trials against" exact="ZIKV" post="[97]. However, none of these compounds has yet been"/>
  <result pre="in recent years with the potential to be drugs for" exact="ZIKV" post="is presented in Table 6. In addition, the following"/>
  <result pre="targets that have been frequently implicated for potential discovery of" exact="ZIKV" post="drugs and are thus further discussed below. Viral proteins"/>
  <result pre="drugs and are thus further discussed below. Viral proteins as" exact="ZIKV" post="drug targets: Viral glycoproteins play important roles for virus"/>
  <result pre="In general, small molecules interfering with the function of any" exact="ZIKV" post="viral proteins should have the potential to restrict virus"/>
  <result pre="potential to restrict virus replication and prevent from progress of" exact="ZIKV" post="related pathogenesis and diseases. Envelope glycoprotein inhibitors too are"/>
  <result pre="in green tea has exhibited inhibition to the entry of" exact="ZIKV" post="into the host cell [114]. Protease inhibitors: ZIKV being"/>
  <result pre="entry of ZIKV into the host cell [114]. Protease inhibitors:" exact="ZIKV" post="being a flavivirus also possesses the NS2B-NS3 protease. Many"/>
  <result pre="protease and surprisingly, some of them were found to inhibit" exact="ZIKV" post="protease activity [108,115]. NS3 helicase inhibitors: These inhibitors bind"/>
  <result pre="are experimentally validated [116]. NS4B inhibitors: Very few studies on" exact="ZIKV" post="NS4B protein inhibition are performed so far, mainly because"/>
  <result pre="developing resistant viruses [117,118,119]. NS5 methyltransferase inhibitors: The structure of" exact="ZIKV" post="MTase with the S-adenosyl-L-methionine (SAM) analog, sinefungin was recently"/>
  <result pre="values &amp;lt;10 mM [110]. Host proteins as drug targets: Since" exact="ZIKV" post="like other flaviviruses contains a small genome, the host"/>
  <result pre="the viral protein functions could be an attractive target for" exact="ZIKV" post="drug discovery. Moreover, broad-spectrum strategy to target host cell"/>
  <result pre="inhibit the virus-induced cytopathic effects (CPE) of several flaviviruses, including" exact="ZIKV" post="(EC50 = 142.9 mg/mL) [126]. However, poor inhibition of"/>
  <result pre="indicates that it is not a suitable candidate as a" exact="ZIKV" post="drug [111]. Other tested nucleoside biosynthesis inhibitors showed better"/>
  <result pre="promising lead candidates for further development particularly as antivirals against" exact="ZIKV" post="[127]. BCX4430 an adenosine nucleoside analog has shown EC50"/>
  <result pre="from mortality induced by a Malaysian strain (P 6–740) of" exact="ZIKV" post="[128]. This protective efficacy of BCX4430 encourages its further"/>
  <result pre="an adenosine nucleoside analog, has also exhibited antiviral activity against" exact="ZIKV" post="in vitro with EC50 at the sub-micro molar range"/>
  <result pre="of a compound library of 100,000 small molecules based on" exact="Zika" post="RNA-dependent RNA polymerase (RdRp) structure, ten lead compounds were"/>
  <result pre="these compounds, 3-chloro-N-[(amino)carbonothioyl]-1-benzothiophene-2-carbox-amide (TPB), a non-nucleoside, was found to inhibit" exact="ZIKV" post="replication with an EC50 in submicromolar concentration (0.94 μM)"/>
  <result pre="that the compound binds to the catalytic site of the" exact="ZIKV" post="RdRp, acting as an allosteric agent to block the"/>
  <result pre="vivo studies (25 mg/kg) in animals (immunocompetent mice) infected with" exact="ZIKV" post="and treating with the compound, TPB showed a reduction"/>
  <result pre="h. Thus, TPB appears to be a promising compound against" exact="ZIKV" post="infection [130]. Another non-nucleoside inhibitor, emetine was reported to"/>
  <result pre="[130]. Another non-nucleoside inhibitor, emetine was reported to potently inhibit" exact="ZIKV" post="NS5 RNA polymerase activity by binding to its active"/>
  <result pre="and significantly reduced the levels of both NS1 protein and" exact="ZIKV" post="RNA in serum and liver, respectively [131]. Host cell"/>
  <result pre="Host cell lipid biosynthesis inhibitors: Viral infections including dengue and" exact="ZIKV" post="are known to be associated with alterations in the"/>
  <result pre="pathway of cholesterol could be an attractive therapeutic approach for" exact="ZIKV" post="drug discovery. As a part of cell-based screening of"/>
  <result pre="FDA-approved drugs, Lovastatin, an HMG-CoA reductase inhibitor was tested against" exact="ZIKV" post="and found to be potent through a dose–response assay"/>
  <result pre="discover PHA-690509, a cyclin- dependent kinase inhibitor (CDKi), that inhibited" exact="ZIKV" post="infection with an EC50 value of 1.72 mM [94]."/>
  <result pre="tested by the group to identify nine that could inhibit" exact="ZIKV" post="replication. Among these inhibitors, seliciclib (a purine analog, also"/>
  <result pre="also known as roscovitine) and RGB-286147 were found to inhibit" exact="ZIKV" post="infection at sub micro molar concentrations [95]. From these"/>
  <result pre="that one or more host CDKs might be important for" exact="ZIKV" post="replication process as flaviviruses are not known to encode"/>
  <result pre="uncontrolled) to be a target for discovery of compounds against" exact="ZIKV" post="infection [137]. The inhibitors for the receptor seem to"/>
  <result pre="only one known disruptor, celgosvir (6-O-buta-noyl castanospermine) was tested against" exact="ZIKV" post="that showed poor activity in a CPE- based assay"/>
  <result pre="yet fully understood [141]. It was identified through screening against" exact="ZIKV" post="in SNB-19 cells showing an EC50 value of 0.37"/>
  <result pre="has yet been approved by FDA for the treatment of" exact="ZIKV" post="infection, numerous small molecules have been identified that have"/>
  <result pre="which may provide completely new class of antiviral drugs including" exact="Zika" post="drugs. The approaches should include knowledge-based drug repurposing [143],"/>
  <result pre="against ZIKV. Pursuit of repurposing strategy on known drugs against" exact="ZIKV" post="revealed that a few antimalarial drugs do possess anti-ZIKV"/>
  <result pre="antimalarial aminoquinolines, Quinacrine (QC), Mefloquine (MQ), and GSK369796 active against" exact="ZIKV" post="in in vitro assay [41]. Activities against ZIKV of"/>
  <result pre="active against ZIKV in in vitro assay [41]. Activities against" exact="ZIKV" post="of the three aminoquinolines were found to be: EC50"/>
  <result pre="to reduce filovirus infections in vitro and in vivo, including" exact="DENV" post="infection [160]. Therefore, these novel host-based targets have the"/>
  <result pre="siRNA [144] and interacting peptides [147] could be useful for" exact="ZIKV" post="drug discovery. In silico structural-bioinformatics-based methodologies and frameworks have"/>
  <result pre="and frameworks have also been developed for the design of" exact="ZIKV" post="antibodies. One of these methodologies deals with RosettaAntibodyDesign (RAbD)"/>
  <result pre="we’ve got to think.�?Ernest Rutherford This review article on the" exact="Zika" post="virus covers the following stages of modern computer-assisted approaches"/>
  <result pre="following stages of modern computer-assisted approaches in the characterization of" exact="Zika" post="virus, risk assessment, and the prevention as well as"/>
  <result pre="characterization: modelling of disease spread mechanisms, vectors, and reservoirs of" exact="ZIKV" post="(and emerging pathogens in general); (b)Internal characterization: bioinformatics-based sequence"/>
  <result pre="stages provide a holistic and proactive step-by-step approach toward combating" exact="ZIKV" post="and potential future pathogens using computational methods. 5.1. Quantitative"/>
  <result pre="potential future pathogens using computational methods. 5.1. Quantitative Characterization of" exact="ZIKV" post="Infection In the realm of mathematical epidemiology discussed in"/>
  <result pre="the SIR model have been explored for the prediction of" exact="ZIKV" post="infection [30,31,32,33,34,35,36]. Besides SIR-type models, public health management in"/>
  <result pre="and associated computational tools. Because viruses are very complex (e.g.," exact="ZIKV" post="has around 11,000 bases in its RNA), the sequences"/>
  <result pre="5) the results on applications of alignment-free methods to the" exact="Zika" post="virus based on the structure (sequence)-property similarity principle [79]"/>
  <result pre="of the orthogonal variables or PCs derived from the calculated" exact="ZIKV" post="RNA sequence descriptors is evident from the PC1 versus"/>
  <result pre="plot in Figure 4 which can clearly separate the African" exact="ZIKV" post="sequences from those from Asia and South America. With"/>
  <result pre="the SOM approach (Figure 5) is even more interesting. Here" exact="ZIKV" post="sequences from various countries and regions are clearly separated"/>
  <result pre="and pathogenicity. 5.3. Computer-Assisted Vaccine Design Development of vaccines against" exact="ZIKV" post="is being attempted. But as of now, no vaccine"/>
  <result pre="as of now, no vaccine is available for use in" exact="Zika" post="Virus infected patients. Traditional vaccine development methods with its"/>
  <result pre="made to assist in this agenda, and designs for a" exact="Zika" post="virus vaccine have already been advanced using these procedures"/>
  <result pre="sphere. 5.4. Anti-Zika Drug Discovery Since a 3D structure of" exact="ZIKV" post="protein is now known, discovery for potential anti ZIKV"/>
  <result pre="of ZIKV protein is now known, discovery for potential anti" exact="ZIKV" post="drugs can be accomplished through a combination of structure-based"/>
  <result pre="important to note that even though the 3D structure of" exact="ZIKV" post="proteins are known, specific features, such as polarization factors,"/>
  <result pre="addition, alternative targets of established 3D protein structures implicated for" exact="ZIKV" post="proteins should also be explored for ZIKV drugs. Although"/>
  <result pre="structures implicated for ZIKV proteins should also be explored for" exact="ZIKV" post="drugs. Although pharmacophore modeling has demonstrated many successes in"/>
  <result pre="summary, it may be commented that for accomplishing a successful" exact="ZIKV" post="drug discovery program, the research team should have good"/>
  <result pre="review for vaccine design; T.D. did the computation of the" exact="Zika" post="genome data for the gR values for all 310"/>
  <result pre="for all 310 sequences available; M.V. performed clustering analysis of" exact="ZIKV" post="sequences; S.C.B., S.M., A.N., A.K.B. wrote the manuscript. Funding"/>
  <result pre="−0.07488 −0.03129 References References 1.World Health Organization (WHO) Report on" exact="Zika" post="VirusAvailable online: http://www.who.int/emergencies/zika-virus/mediacentre/press-releases/en/(accessed on 7 July 2019) 2.MacNamaraF.N.Zika virus:"/>
  <result pre="History, Emergence, Biology, and Prospects for ControlAntiviral Res.2016130698010.1016/j.antiviral.2016.03.01026996139 5.MarchetteN.J.GarciaR.RudnickA.Isolation of" exact="Zika" post="virus from Aedes aegypti mosquitoes in MalaysiaAm. J. Trop."/>
  <result pre="R. Soc. Trop. Med. Hyg.19817538939310.1016/0035-9203(81)90100-06275577 7.LiangD.LeungR.K.K.LeeS.S.KamK.M.Insights into intercontinental spread of" exact="Zika" post="virusPLoS ONE201712e017671010.1371/journal.pone.017671028448611 8.WHO Report on Zika VIRUS, Microcephaly and"/>
  <result pre="into intercontinental spread of Zika virusPLoS ONE201712e017671010.1371/journal.pone.017671028448611 8.WHO Report on" exact="Zika" post="VIRUS, Microcephaly and Guillain–Barré SyndromeAvailable online: http://apps.who.int/iris/bitstream/handle/10665/204609/zikasitrep_10Mar2016_eng.pdf;jsessionid=F9E4895E6176562081D34C0DED1A6550?sequence=1(accessed on 7"/>
  <result pre="on 7 July 2019) 9.NandyA.BasakS.C.The Epidemic that Shook the World—The" exact="Zika" post="Virus RampageExplor. Res. Hypothesis Med.20172435610.14218/ERHM.2017.00018 10.ArmstrongN.HouW.TangQ.Biological and historical overview"/>
  <result pre="Virus RampageExplor. Res. Hypothesis Med.20172435610.14218/ERHM.2017.00018 10.ArmstrongN.HouW.TangQ.Biological and historical overview of" exact="Zika" post="virusWorld J. Virol.201761810.5501/wjv.v6.i1.128239566 11.FayeO.FreireC.C.M.IamarinoA.FayeO.de OlivieraJ.V.C.DialloM.ZanottoP.M.A.SallA.A.Molecular Evolution of Zika Virus"/>
  <result pre="overview of Zika virusWorld J. Virol.201761810.5501/wjv.v6.i1.128239566 11.FayeO.FreireC.C.M.IamarinoA.FayeO.de OlivieraJ.V.C.DialloM.ZanottoP.M.A.SallA.A.Molecular Evolution of" exact="Zika" post="Virus during Its Emergence in the 20th CenturyPLoS Negl."/>
  <result pre="16.SutharM.S.DiamondM.S.GaleM.Jr.West Nile virus infection and immunityNat. Rev. Microbiol.20131111512810.1038/nrmicro295023321534 17.NandyA.DeyS.BasakS.C.Bielinska-WazD.WazP.Characterizing the" exact="Zika" post="Virus Genome—A Bioinformatics StudyCurr. Comp. Aided Drug Des.201612879710.2174/1573409912666160401115812 18.KindhauserM.K.AllenT.FrankV.SanthanaR.S.DyeC.Zika:"/>
  <result pre="a mosquito-borne virusBull. World Health Organ.20169467568610.2471/BLT.16.17108227708473 19.WHO Situation Report on" exact="Zika" post="Virus, 9th March 2017Available online: http://apps.who.int/iris/bitstream/10665/254714/1/zikasitrep10Mar17-eng.pdf(accessed on 7 July"/>
  <result pre="on 3 September 2019) 22.Cao-LormeauV.M.BlakeA.MonsS.LastereS.RocheC.VanhomwegenJ.DubT.BaudouinL.TeissierA.LarreP.et al.Guillain-Barré Syndrome outbreak associated with" exact="Zika" post="virus infection in French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 23.ParraB.LizarazoJ.JorgeA.Jimenez-ArangoJ.A.Zea-VaraA.F.Gonzalez-ManriqueG.VargasJ.AngaritaJ.A.ZunigaG.Lopez-GonzalezR.et"/>
  <result pre="French Polynesia: A case-control studyLancet20163871531153910.1016/S0140-6736(16)00562-626948433 23.ParraB.LizarazoJ.JorgeA.Jimenez-ArangoJ.A.Zea-VaraA.F.Gonzalez-ManriqueG.VargasJ.AngaritaJ.A.ZunigaG.Lopez-GonzalezR.et al.Guillain–Barré Syndrome Associated with" exact="Zika" post="Virus Infection in ColombiaN. Engl. J. Med.20163751513152310.1056/NEJMoa160556427705091 24.Zika Virus"/>
  <result pre="29.HethcoteH.The Mathematics of Infectious DiseasesSIAM Rev.20004259965310.1137/S0036144500371907 30.SuparitP.WiratsudakulA.ModchangC.A mathematical model for" exact="Zika" post="virus transmission dynamics with a time-dependent mosquito biting rateTheor."/>
  <result pre="Med. Model.2018151110.1186/s12976-018-0083-z30064447 31.NishiuraH.MizumotoK.Villamil-GomezW.E.Rodriguez-MoralesA.J.Preliminary estimation of the basic reproduction number of" exact="Zika" post="virus infection during Colombia epidemic, 2015–2016Trav. Med. Infect. Dis.20161427427610.1016/j.tmaid.2016.03.01627060613"/>
  <result pre="virus associated with microcephalyN. Eng. J. Med.201637495195810.1056/NEJMoa160065126862926 33.AgustoF.B.BewickS.FaganW.F.Mathematical model of" exact="Zika" post="virus with vertical transmissionInfect. Dis. Model.20172324426710.1016/j.idm.2017.05.00329928740 34.PadmanabhanP.SeshaiyerP.Castillo-ChavezC.Mathematical modeling, analysis"/>
  <result pre="Model.20172324426710.1016/j.idm.2017.05.00329928740 34.PadmanabhanP.SeshaiyerP.Castillo-ChavezC.Mathematical modeling, analysis and simulation of the spread of" exact="Zika" post="with influence of sexual transmission and preventive measuresLett. Bioinform.2017414816610.1080/23737867.2017.1319746"/>
  <result pre="Strategies to Combat the MenaceBasakS.C.BhattacharjeeA.K.NandyA.NovaNew York, NY, USA2019129152 36.WiratsudakulA.SuparitP.ModchangC.Dynamics of" exact="Zika" post="virus outbreaks: An overview of mathematical modeling approachesPeerJ20186e452610.7717/peerj.452629593941 37.HanB.MajumdarS.CalmonF.P.GlicksbergB.S.HoreshR.KumarA.PererA.von"/>
  <result pre="37.HanB.MajumdarS.CalmonF.P.GlicksbergB.S.HoreshR.KumarA.PererA.von MarschallE.B.WeiD.MojsilovicA.et al.Confronting data sparsity to identify potential sources of" exact="Zika" post="virus spillover infection among primatesEpidemics201927596510.1016/j.epidem.2019.01.00530902616 38.SahooM.JenaL.DafS.KumarS.Virtual Screening for Potential"/>
  <result pre="primatesEpidemics201927596510.1016/j.epidem.2019.01.00530902616 38.SahooM.JenaL.DafS.KumarS.Virtual Screening for Potential Inhibitors of NS3 Protein of" exact="Zika" post="VirusGenomics Inform.20161410411110.5808/GI.2016.14.3.10427729840 39.SinghA.JanaN.K.Discovery of potential Zika virus RNA polymerase"/>
  <result pre="of NS3 Protein of Zika VirusGenomics Inform.20161410411110.5808/GI.2016.14.3.10427729840 39.SinghA.JanaN.K.Discovery of potential" exact="Zika" post="virus RNA polymerase inhibitors by docking-based virtual screeningComp. Biol."/>
  <result pre="activities of selected antimalarials against dengue virus type 2 and" exact="Zika" post="virusAntivir. Res.201713714115010.1016/j.antiviral.2016.11.01527889529 42.SinigagliaA.RiccettiS.TrevisanM.BarzonL.In silico approaches to Zika virus drug"/>
  <result pre="type 2 and Zika virusAntivir. Res.201713714115010.1016/j.antiviral.2016.11.01527889529 42.SinigagliaA.RiccettiS.TrevisanM.BarzonL.In silico approaches to" exact="Zika" post="virus drug discoveryExpert Opin. Drug Discov.20181382583510.1080/17460441.2018.151590930160181 43.LucaS.MihaescuT.History of BCG"/>
  <result pre="brief reviewInt. J. Gen. Med.2009219520010.2147/IJGM.S628120360904 47.GuyB.GuirakhooF.BarbanV.HiggsS.MonathT.P.LangJ.Preclinical and clinical development of" exact="YFV" post="17D-based chimeric vaccines against dengue, West Nile and Japanese"/>
  <result pre="and clinical development of YFV 17D-based chimeric vaccines against dengue," exact="West Nile" post="and Japanese encephalitis virusesVaccine20102863264910.1016/j.vaccine.2009.09.09819808029 48.WHO Vaccine Pipeline TrackerAvailable online:"/>
  <result pre="al.Computational prediction and analysis of potential antigenic CTL epitopes in" exact="Zika" post="virus: A first step towards vaccine developmentInfect. Genet. Evol.20164518719710.1016/j.meegid.2016.08.03727590716"/>
  <result pre="and Immunoinformatics Probing Disclose the Epitope Based Peptide Vaccine Against" exact="Zika" post="Virus Envelope GlycoproteinInd. J. Pharma. Biol. Res.201424457 54.MirzaM.U.RafiqueS.AliA.MunirM.IkramN.MananA.Salo-AhenO.M.H.IdreesM.Towards peptide"/>
  <result pre="Envelope GlycoproteinInd. J. Pharma. Biol. Res.201424457 54.MirzaM.U.RafiqueS.AliA.MunirM.IkramN.MananA.Salo-AhenO.M.H.IdreesM.Towards peptide vaccines against" exact="Zika" post="virus: Immunoinformatics combined with molecular dynamics simulations to predict"/>
  <result pre="combined with molecular dynamics simulations to predict antigenic epitopes of" exact="Zika" post="viral proteinsSci. Rep.201663731310.1038/srep4463327934901 55.DeyS.DasS.NandyA.Characterization of Zika and Other Human"/>
  <result pre="predict antigenic epitopes of Zika viral proteinsSci. Rep.201663731310.1038/srep4463327934901 55.DeyS.DasS.NandyA.Characterization of" exact="Zika" post="and Other Human Infecting Flavivirus Envelope Proteins and Determination"/>
  <result pre="Epitope RegionsEC Microbiol.201782946 56.DarH.ZaheerT.RehmanM.T.AliA.JavedA.KhanG.A.BabarM.M.WaheedY.Prediction of promiscuous T-cell epitopes in the" exact="Zika" post="virus polyprotein: An in silico approachAsian Pac. J. Trop."/>
  <result pre="Trop. Med.2016984485010.1016/j.apjtm.2016.07.00427633296 57.Dos Santos FrancoL.Oliveira VidalP.AmorimJ.H.In silico design of a" exact="Zika" post="virus non-structural protein 5 aiming vaccine protection against zika"/>
  <result pre="human populationsJ. Biomed. Sci.2017248810.1186/s12929-017-0395-z29169357 58.RichnerJ.M.HimansuS.DowdK.A.ButlerS.L.SalazarV.FoxJ.M.JulanderJ.G.TangW.W.ShrestaS.PiersonT.C.et al.Modified mRNA vaccines protect against" exact="Zika" post="virus infectionCell20171681114112510.1016/j.cell.2017.02.01728222903 59.NandyA.GhoshA.NandyP.Numerical characterization of protein sequences and application"/>
  <result pre="of Human PapillomavirusCancer Inform.20161511610.4137/CIN.S39071 62.DeyS.NandyA.BasakS.C.NandyP.DasS.A Bioinformatics approach to designing a" exact="Zika" post="virus vaccineComput. Biol. Chem.20176814315210.1016/j.compbiolchem.2017.03.00228342423 63.CellisE.Getting peptide vaccines to work:"/>
  <result pre="ChoudhuryA.ZhukovN.VrackoM.Mathematical Characterization of Protein Transmembrane RegionsSci. World. J.2013201360783010.1155/2013/60783023690747 81.VrackoM.BasakS.C.NandyA.SenD.Clustering of" exact="Zika" post="viruses originating from different geographical regions using computational sequence"/>
  <result pre="drug development parametersCurr. Opin. Drug Discov.20011210210910.1124/pr.112.007336 90.MottinM.BorbaJ.V.V.B.BragaR.C.TorresP.H.M.MartiniM.C.Proenca-ModenaJ.L.JudiceC.C.CostaF.T.M.EkinsS.PerrymanA.L.et al.The A–Z of" exact="Zika" post="drug discoveryDrug Discov. Today20182310.1016/j.drudis.2018.06.01429935345 91.WattersonD.ModhiranN.YoungP.R.The many faces of the"/>
  <result pre="Res.20002823524210.1093/nar/28.1.23510592235 93.BarrowsN.J.CamposR.K.PowellS.T.PrasanthK.R.Schott-LernerG.Soto-AcostaR.Galarza-MuñozG.McGrathE.L.Urrabaz-GarzaR.GaoJ.et al.A screen of FDA-approved drugs for inhibitors of" exact="Zika" post="virus infectionCell Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 94.XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors"/>
  <result pre="virus infectionCell Host Microbe20162025927010.1016/j.chom.2016.07.00427476412 94.XuM.LeeE.M.WenZ.ChengY.HuangW.K.QianX.TcwJ.KouznetsovaJ.OgdenS.C.HammackC.et al.Identification of small-molecule inhibitors of" exact="Zika" post="virus infection and induced neural cell death via a"/>
  <result pre="libraryF1000Research20165252310.12688/f1000research.9648.127909576 96.ZhuS.ZhangC.HuangL.S.ZhangX.Q.XuY.FangX.ZhouJ.WuM.SchooleyR.T.HuangZ.et al.Discovery and Computational Analyses of Novel Small Molecule" exact="Zika" post="Virus InhibitorsMolecules201924146510.3390/molecules24081465 97.Wilder-SmithA.VanniceK.DurbinA.HombachJ.ThomasS.J.ThevarjanI.SimmonsC.P.Zika vaccines and therapeutics: Landscape analysis and"/>
  <result pre="challenges aheadBMC Med.2018168410.1186/s12916-018-1067-x29871628 98.DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.LoiolaE.C.DiasA.A.SilvaF.J.M.AliotaM.T.et al.Chloroquine, an Endocytosis Blocking Agent, Inhibits" exact="Zika" post="Virus Infection in Different Cell ModelsViruses2016832210.3390/v812032227916837 99.DevillersJ.Repurposing drugs for"/>
  <result pre="Infection in Different Cell ModelsViruses2016832210.3390/v812032227916837 99.DevillersJ.Repurposing drugs for use against" exact="Zika" post="virus infectionSAR QSAR Environ. Res.20182910311510.1080/1062936X.2017.141164229299939 100.OguntadeS.RamharackP.SolimanM.E.S.Characterizing the ligand-binding landscape"/>
  <result pre="virus infectionSAR QSAR Environ. Res.20182910311510.1080/1062936X.2017.141164229299939 100.OguntadeS.RamharackP.SolimanM.E.S.Characterizing the ligand-binding landscape of" exact="Zika" post="NS3 helicase-promising lead compounds as potential inhibitorsFuture Virol.20171226127310.2217/fvl-2017-0014 101.HercíkK.KozakJ.SalaM.DejmekM.XuL.BeiZ.ZhangD.DouY.WangH.Viral"/>
  <result pre="101.HercíkK.KozakJ.SalaM.DejmekM.XuL.BeiZ.ZhangD.DouY.WangH.Viral polymerase inhibitors T-705 and T-1105 are potential inhibitors of" exact="Zika" post="virus replicationAntivir. Res.201713713113310.1016/j.antiviral.2016.11.02027902932 102.MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.et al.Advances in Developing Therapies to"/>
  <result pre="virus replicationAntivir. Res.201713713113310.1016/j.antiviral.2016.11.02027902932 102.MunjalA.KhandiaR.DhamaK.SachanS.KarthikK.TiwariR.MalikY.S.KumarD.SinghR.K.IqbalH.M.N.et al.Advances in Developing Therapies to Combat" exact="Zika" post="Virus: Current Knowledge and Future PerspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 103.EkinsS.MietchenD.CoffeeM.StrattonT.P.FreundlichJ.S.Freitas-JuniorL.MuratovE.Siqueira-NetoJ.WilliamsA.J.AndradeC.Open drug"/>
  <result pre="Knowledge and Future PerspectivesFront. Microbiol.20178146910.3389/fmicb.2017.0146928824594 103.EkinsS.MietchenD.CoffeeM.StrattonT.P.FreundlichJ.S.Freitas-JuniorL.MuratovE.Siqueira-NetoJ.WilliamsA.J.AndradeC.Open drug discovery fore the" exact="Zika" post="virusF1000Research2016515010.12688/f1000research.8013.127134728 104.MicewiczE.D.KhachatoorianR.FrenchS.W.RuchalaP.Identification of novel small-molecule inhibitors of Zika virus"/>
  <result pre="fore the Zika virusF1000Research2016515010.12688/f1000research.8013.127134728 104.MicewiczE.D.KhachatoorianR.FrenchS.W.RuchalaP.Identification of novel small-molecule inhibitors of" exact="Zika" post="virus infectionBioorg. Med. Chem. Lett.20182845245810.1016/j.bmcl.2017.12.01929258771 105.NcubeN.B.RamharackP.SolimanM.E.S.An &quot;All-In-One�? Pharmacophoric Architecture"/>
  <result pre="Biotechnol.201818579981410.1007/s12010-017-2690-229349531 106.SarukhanyanE.ShityakovS.DandekarT.In Silico Designed Axl Receptor Blocking Drug Candidates Against" exact="Zika" post="VirusACS Omega201835281529010.1021/acsomega.8b0022330023915 107.PanT.PengZ.TanL.ZouF.ZhouN.LiuB.LiangL.ChenC.LiuJ.WuL.Nonsteroidal Anti-inflammatory Drugs Potently Inhibit the Replication"/>
  <result pre="VirusACS Omega201835281529010.1021/acsomega.8b0022330023915 107.PanT.PengZ.TanL.ZouF.ZhouN.LiuB.LiangL.ChenC.LiuJ.WuL.Nonsteroidal Anti-inflammatory Drugs Potently Inhibit the Replication of" exact="Zika" post="Viruses by Inducing the Degradation of AXLJ. Virol.2018269210.1128/JVI.01018-1830068645 108.LimH.J.NguyenT.T.KimN.M.ParkJ.S.JangT.J.KimD.Inhibitory"/>
  <result pre="structure activity relationshipBiotechnol. Lett.20173941544210.1007/s10529-016-2261-627885509 109.JainR.ColomaJ.Garcia-SastreA.AggarwalA.K.Structure of the NS3 helicase from" exact="Zika" post="virusNat. Struct. Mol. Biol.20162375275410.1038/nsmb.325827399257 110.EyerL.NenckaR.HuvarovaI.PalusM.Joao AlvesM.GouldE.A.De ClercqE.RůžekD.Nucleoside Inhibitors of"/>
  <result pre="Zika virusNat. Struct. Mol. Biol.20162375275410.1038/nsmb.325827399257 110.EyerL.NenckaR.HuvarovaI.PalusM.Joao AlvesM.GouldE.A.De ClercqE.RůžekD.Nucleoside Inhibitors of" exact="Zika" post="VirusJ. Infect. Dis.201621470771110.1093/infdis/jiw22627234417 111.HercikK.BryndaJ.NenckaR.BouraE.Structural basis of Zika virus methyltransferase"/>
  <result pre="ClercqE.RůžekD.Nucleoside Inhibitors of Zika VirusJ. Infect. Dis.201621470771110.1093/infdis/jiw22627234417 111.HercikK.BryndaJ.NenckaR.BouraE.Structural basis of" exact="Zika" post="virus methyltransferase inhibition by sinefunginArch. Virol.20171622091209610.1007/s00705-017-3345-x28357511 112.AdcockR.S.ChuY.K.GoldenJ.E.ChungD.H.Evaluation of anti-Zika"/>
  <result pre="high-throughput screen assayAntivir. Res.2017138475610.1016/j.antiviral.2016.11.01827919709 113.HanY.MesplèdeT.Investigational drugs for the treatment of" exact="Zika" post="virus infection: A preclinical and clinical updateExpert Opin. Investig."/>
  <result pre="updateExpert Opin. Investig. Drugs20182795196210.1080/13543784.2018.1548609 114.CarneiroB.M.BatistaM.N.BragaA.C.S.NogueiraM.L.RahalP.The green tea molecule EGCG inhibits" exact="Zika" post="virus entryVirology201649621521810.1016/j.virol.2016.06.01227344138 115.RoyA.LimL.SrivastavaS.LuY.SongJ.Solution conformations of Zika NS2B-NS3pro and its"/>
  <result pre="tea molecule EGCG inhibits Zika virus entryVirology201649621521810.1016/j.virol.2016.06.01227344138 115.RoyA.LimL.SrivastavaS.LuY.SongJ.Solution conformations of" exact="Zika" post="NS2B-NS3pro and its inhibition by natural products from edible"/>
  <result pre="restricts genomic RNA replicationAntivir. Res.20139916517110.1016/j.antiviral.2013.05.01123735301 120.StephenP.BazM.BolvinG.LinS.X.Structural insight into NS5 of" exact="Zika" post="virus leading to the discovery of MTase inhibitorsJ. Am."/>
  <result pre="Targets2016171560157610.2174/138945011766615120912375126648061 128.JulanderJ.G.SiddharthanV.EvansJ.TaylorR.TolbertK.ApuliC.StewartJ.CollinsP.GebreM.NeilsonS.et al.Efficacy of the broad-spectrum antiviral compound BCX4430 against" exact="Zika" post="virus in cell culture and in a mouse modelAntivir."/>
  <result pre="modelAntivir. Res.2017137142210.1016/j.antiviral.2016.11.00327838352 129.DengY.Q.ZhangN.N.LiC.F.TianM.HaoJ.-N.XieX.-P.ShiP.-Y.QinC.-F.Adenosine analog NITD008 is a potent inhibitor of" exact="Zika" post="virusOpen Forum Infect. Dis.20163ofw17510.1093/ofid/ofw17527747251 130.PattnaikA.PalermoN.SahooB.R.YuanZ.HuD.AnnamalaiA.S.VuH.L.X.CorreasI.PrathipatiP.K.DestacheC.J.et al.Discovery of a non-nucleoside"/>
  <result pre="130.PattnaikA.PalermoN.SahooB.R.YuanZ.HuD.AnnamalaiA.S.VuH.L.X.CorreasI.PrathipatiP.K.DestacheC.J.et al.Discovery of a non-nucleoside RNA polymerase inhibitor for blocking" exact="Zika" post="virus replication through in silico screeningAntivir. Res.2018151788610.1016/j.antiviral.2017.12.01629274845 131.YangS.XuM.LeeE.M.ShiryaevS.A.HeS.SunW.ChengY.-S.HuX.TharappelA.M.LuB.et al.Emetine"/>
  <result pre="virus replication through in silico screeningAntivir. Res.2018151788610.1016/j.antiviral.2017.12.01629274845 131.YangS.XuM.LeeE.M.ShiryaevS.A.HeS.SunW.ChengY.-S.HuX.TharappelA.M.LuB.et al.Emetine inhibits" exact="Zika" post="and Ebola virus infections through two molecular mechanisms: Inhibiting"/>
  <result pre="response and autophagyFront. Microbiol.201451710.3389/fmicb.2014.0026624478763 140.KuivanenS.BespalovM.M.NandaniaJ.IanevskiA.VelagapudiV.De BrabanderJ.K.KainovD.E.VapalahtiO.Obatoclax, saliphenylhalamide and gemcitabine inhibit" exact="Zika" post="virus infection in vitro and differentially affect cellular signaling,"/>
  <result pre="with broad antiviral effectsPLoS Pathog.20128e100297610.1371/journal.ppat.100297623133371 142.ChengF.MurrayJ.L.RubinD.H.Drug repurposing: New treatments for" exact="Zika" post="virus infection?Trends Mol. Med.20162291992110.1016/j.molmed.2016.09.00627692879 143.YangH.T.JuJ.H.WongY.T.ShmulevichI.ChiangJ.H.Literature-based discovery of new candidates"/>
  <result pre="of new candidates for drug repurposingBrief Bioinform.20171848849710.1093/bib/bbw03027113728 144.GiuliettiM.RighettiA.CianfrugliaL.ŠabanovićB.ArmeniT.PrincipatoG.PivaF.To accelerate the" exact="Zika" post="beat: Candidate design for RNA interference-based therapyVirus Res.201825513314010.1016/j.virusres.2018.07.01030031046 145.MengX.Y.LuoY.AnwarM.N.SunY.GaoY.ZhangH.MunirM.QiuH.-J.Long"/>
  <result pre="predicted human-Zika virus protein-protein interactionsComput. Biol. Chem.20177118018710.1016/j.compbiolchem.2017.10.01129112936 148.GoertzG.P.AbboS.R.FrosJ.J.PijlmanG.P.Functional RNA during" exact="Zika" post="virus 980 infectionVirus Res.2017254415310.1016/j.virusres.2017.08.01528864425 149.HermannT.Small molecules targeting viral RNAWiley"/>
  <result pre="by Flaviviridae virusesFront. Microbiol.20167123310.3389/fmicb.2016.0123327610098 155.LiC.ZhuX.JiX.QuanquinN.DengY.-Q.TianM.AliyariR.ZuoX.YuanL.AfridiS.K.et al.Chloroquine, a FDA-approved drug, prevents" exact="Zika" post="Virus infection and its associated congenital microcephaly in miceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372"/>
  <result pre="in miceEBioMedicine20172418919410.1016/j.ebiom.2017.09.03429033372 156.ShiryaevS.A.MesciP.PintoA.FernandesI.SheetsN.ShrestaS.FarhyC.HuangC.-T.StronginA.Y.MuotriA.R.et al.Repurposing of the anti-malaria drug chloroquine for" exact="Zika" post="virus treatment and prophylaxisSci. Rep.201771577110.1038/s41598-017-15467-629150641 157.HanY.MespledeT.XuH.QuanY.WainbergM.A.The antimalarial drug amodiaquine"/>
  <result pre="al.High-content screening in hPSC-neural progenitors identifies drug candidates that inhibit" exact="Zika" post="virus infection in fetal-like organoids and adult brainCell Stem"/>
  <result pre="brainCell Stem Cell20172127428310.1016/j.stem.2017.06.01728736217 159.CaoB.ParnellL.A.DiamondM.S.MysorekarI.U.Inhibition of autophagy limits vertical transmission of" exact="Zika" post="virus in pregnant miceJ. Exp. Med.20172142303231310.1084/jem.2017095728694387 160.WarfieldK.L.WarrenT.K.QiuX.WellsJ.MireC.E.GeisbertJ.B.StuthmanK.S.GarzaN.L.Van TongerenS.A.ShurtleffA.C.et al.Assessment"/>
  <result pre="invertebrate hosts’Phil. Trans. R. Soc. B201437010.1098/rstb.2014.030725750231 168.GaoD.LouY.HeD.PorcoT.C.KuangY.ChowellG.RuanS.Prevention and Control of" exact="Zika" post="as a Mosquito-Borne and Sexually Transmitted Disease: A Mathematical"/>
  <result pre="Attribution License from [12]. Figure 2 Phylogenetic tree of 22" exact="ZIKV" post="genome sequences [17]. Each sequence is identified with its"/>
  <result pre="Publishers, www.benthamscience.com. Figure 3 The 2D graphical representation of the" exact="Zika" post="virus whole genome (GenBank Locus ID KY241706), methodology as"/>
  <result pre="y-axis. Figure 4 Principal component analysis (PCA) score plots of" exact="ZIKV" post="strains from different continents. Figure 5 Distribution of objects"/>
  <result pre="flavivirus genome including UTRs. Typical sequence length data taken from" exact="ZIKV" post="isolate ZIKV/H. sapiens/Brazil/PE243/2015 (GenBank Locus ID KX197192), complete genome."/>
  <result pre="and translation. pharmaceuticals-12-00157-t002_Table 2Table 2 The pre-epidemics period of the" exact="Zika" post="virus after its detection in 1947. A. africanus: Aedes"/>
  <result pre="after its detection in 1947. A. africanus: Aedes africanus; ZIKV:" exact="Zika" post="virus. Year Country Remarks 1947 Uganda First isolation and"/>
  <result pre="identification of ZIKV. Found in rhesus monkey, R766, caged in" exact="Zika" post="forest. 1948 Uganda Detected in A. africanus mosquitoes. Found"/>
  <result pre="forest. 1948 Uganda Detected in A. africanus mosquitoes. Found in" exact="Zika" post="forest. 1951 Nigeria First instance of ZIKV antibodies in"/>
  <result pre="mosquitoes. Found in Zika forest. 1951 Nigeria First instance of" exact="ZIKV" post="antibodies in human blood, found in children. 1952 Uganda,"/>
  <result pre="found in children. 1952 Uganda, Tanganyika First human cases of" exact="ZIKV" post="infection detected. India ZIKV antibodies found in human blood."/>
  <result pre="Uganda, Tanganyika First human cases of ZIKV infection detected. India" exact="ZIKV" post="antibodies found in human blood. 1953 Malaya, North Borneo,"/>
  <result pre="antibodies found in human blood. 1953 Malaya, North Borneo, Philippines" exact="ZIKV" post="antibodies found in residents. Nigeria ZIKV infection detected in"/>
  <result pre="Malaya, North Borneo, Philippines ZIKV antibodies found in residents. Nigeria" exact="ZIKV" post="infection detected in three persons. 1954 Egypt, Vietnam ZIKV"/>
  <result pre="Nigeria ZIKV infection detected in three persons. 1954 Egypt, Vietnam" exact="ZIKV" post="antibodies found in few residents. 1955 Nigeria ZIKV antibodies"/>
  <result pre="Egypt, Vietnam ZIKV antibodies found in few residents. 1955 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1957 Mozambique ZIKV antibodies"/>
  <result pre="1955 Nigeria ZIKV antibodies found in human blood. 1957 Mozambique" exact="ZIKV" post="antibodies found in human blood. 1958 Uganda Two strains"/>
  <result pre="antibodies found in human blood. 1958 Uganda Two strains of" exact="ZIKV" post="found in A. aegypti mosquitoes in Zika forest. 1960"/>
  <result pre="Two strains of ZIKV found in A. aegypti mosquitoes in" exact="Zika" post="forest. 1960 Angola ZIKV antibodies found in indigenous residents."/>
  <result pre="found in A. aegypti mosquitoes in Zika forest. 1960 Angola" exact="ZIKV" post="antibodies found in indigenous residents. 1961–1962 Central African Republic"/>
  <result pre="ZIKV antibodies found in indigenous residents. 1961–1962 Central African Republic" exact="ZIKV" post="antibodies found in human blood. 1961–1964 Ethiopia ZIKV antibodies"/>
  <result pre="African Republic ZIKV antibodies found in human blood. 1961–1964 Ethiopia" exact="ZIKV" post="antibodies found in human blood. 1962 Senegal ZIKV antibodies"/>
  <result pre="1961–1964 Ethiopia ZIKV antibodies found in human blood. 1962 Senegal" exact="ZIKV" post="antibodies found in human blood. 1963–1964 Central African Republic,"/>
  <result pre="antibodies found in human blood. 1963–1964 Central African Republic, Burkina-Faso" exact="ZIKV" post="antibodies found in human blood. 1963–1965 Ivory Coast ZIKV"/>
  <result pre="Burkina-Faso ZIKV antibodies found in human blood. 1963–1965 Ivory Coast" exact="ZIKV" post="antibodies found in human blood. 1964 Uganda First confirmation"/>
  <result pre="antibodies found in human blood. 1964 Uganda First confirmation that" exact="ZIKV" post="causes human disease.Clinical features reported. 1964–1965 Guinea-Bissau ZIKV antibodies"/>
  <result pre="confirmation that ZIKV causes human disease.Clinical features reported. 1964–1965 Guinea-Bissau" exact="ZIKV" post="antibodies found in human blood. 1964–1966 Togo, Cameroon ZIKV"/>
  <result pre="Guinea-Bissau ZIKV antibodies found in human blood. 1964–1966 Togo, Cameroon" exact="ZIKV" post="antibodies found in human blood. 1965 Niger ZIKV antibodies"/>
  <result pre="Togo, Cameroon ZIKV antibodies found in human blood. 1965 Niger" exact="ZIKV" post="antibodies found in human blood. 1965–1967 Nigeria ZIKV antibodies"/>
  <result pre="1965 Niger ZIKV antibodies found in human blood. 1965–1967 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1967 Benin, Gabon, Liberia"/>
  <result pre="ZIKV antibodies found in human blood. 1967 Benin, Gabon, Liberia" exact="ZIKV" post="antibodies found in human blood. 1966–1967 Uganda, Kenya, Somalia,"/>
  <result pre="antibodies found in human blood. 1966–1967 Uganda, Kenya, Somalia, Morocco" exact="ZIKV" post="antibodies found in human blood. 1967–1969 Uganda ZIKV antibodies"/>
  <result pre="Somalia, Morocco ZIKV antibodies found in human blood. 1967–1969 Uganda" exact="ZIKV" post="antibodies found in human blood. 1968 Kenya ZIKV antibodies"/>
  <result pre="1967–1969 Uganda ZIKV antibodies found in human blood. 1968 Kenya" exact="ZIKV" post="antibodies found in human blood. 1969–1972 Nigeria ZIKV antibodies"/>
  <result pre="1968 Kenya ZIKV antibodies found in human blood. 1969–1972 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1969 Malaysia ZIKV found"/>
  <result pre="1969–1972 Nigeria ZIKV antibodies found in human blood. 1969 Malaysia" exact="ZIKV" post="found in A. aegypti mosquitoes. 1969–1983 Indonesia, Malaysia, Pakistan"/>
  <result pre="ZIKV found in A. aegypti mosquitoes. 1969–1983 Indonesia, Malaysia, Pakistan" exact="ZIKV" post="found in mosquitoes.Sporadic human infections. 1970 Nigeria ZIKV antibodies"/>
  <result pre="Malaysia, Pakistan ZIKV found in mosquitoes.Sporadic human infections. 1970 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1971–1972 Angola ZIKV antibodies"/>
  <result pre="1970 Nigeria ZIKV antibodies found in human blood. 1971–1972 Angola" exact="ZIKV" post="antibodies found in human blood. 1972,1975, 1988,1990 Senegal ZIKV"/>
  <result pre="Angola ZIKV antibodies found in human blood. 1972,1975, 1988,1990 Senegal" exact="ZIKV" post="antibodies found in human blood. 1979 Central African Republic"/>
  <result pre="ZIKV antibodies found in human blood. 1979 Central African Republic" exact="ZIKV" post="antibodies found in human blood. 1980 Nigeria ZIKV antibodies"/>
  <result pre="African Republic ZIKV antibodies found in human blood. 1980 Nigeria" exact="ZIKV" post="antibodies found in human blood. 1984 Uganda ZIKV antibodies"/>
  <result pre="1980 Nigeria ZIKV antibodies found in human blood. 1984 Uganda" exact="ZIKV" post="antibodies found in human blood. 1996–1997 Malaysia ZIKV antibodies"/>
  <result pre="1984 Uganda ZIKV antibodies found in human blood. 1996–1997 Malaysia" exact="ZIKV" post="antibodies found in human blood. 1999 Ivory Coast ZIKV"/>
  <result pre="Malaysia ZIKV antibodies found in human blood. 1999 Ivory Coast" exact="ZIKV" post="antibodies found in human blood. pharmaceuticals-12-00157-t003_Table 3Table 3 A"/>
  <result pre="in human blood. pharmaceuticals-12-00157-t003_Table 3Table 3 A brief summary of" exact="ZIKV" post="epidemics, 2007 to present. Data summarized from [18,19]. Year"/>
  <result pre="home country and passing infection through sexual contact. 2010 Cameroon" exact="ZIKV" post="antibodies found in human blood. 2010–2015 Cambodia, Indonesia, Malaysia,"/>
  <result pre="2010–2015 Cambodia, Indonesia, Malaysia, Philippines, Thailand, Maldives Mosquito transmission of" exact="ZIKV" post="in these countries to travelers who then carried the"/>
  <result pre="their home countries. 2011–2014 French Polynesia Second reported outbreak of" exact="ZIKV" post="infections. Connection with microcephaly and neurological disorders established later."/>
  <result pre="and neurological disorders established later. 2013–2014 Chile, Cook Islands,New Caledonia" exact="ZIKV" post="outbreak. 2013 Tahiti ZIKV isolated from patient’s semen showing"/>
  <result pre="later. 2013–2014 Chile, Cook Islands,New Caledonia ZIKV outbreak. 2013 Tahiti" exact="ZIKV" post="isolated from patient’s semen showing sexual transmissibility. 2014 Zambia"/>
  <result pre="ZIKV isolated from patient’s semen showing sexual transmissibility. 2014 Zambia" exact="ZIKV" post="antibodies found in human blood. 2015 April/May Brazil, Bahia"/>
  <result pre="Brazil, Bahia state National Reference Laboratory, Brazil confirmed, by PCR," exact="ZIKV" post="infections, for the first time in the Americas. 2015"/>
  <result pre="for the first time in the Americas. 2015 July Brazil" exact="Zika" post="cases confirmed by laboratory tests in 12 states. Neurological"/>
  <result pre="America Colombia, Republic of Cabo Verde report confirmed cases of" exact="ZIKV" post="infections.Brazil reported unusual increase in the number of cases"/>
  <result pre="declared a national public health emergency. Brazil reported detection of" exact="ZIKV" post="in amniotic fluid of fetuses with confirmed microcephaly. Suriname,"/>
  <result pre="Suriname, Panama, El Salvador, Guatemala, and Paraguay confirmed cases of" exact="ZIKV" post="infection. The Pan American Health Organization and WHO issued"/>
  <result pre="issued an epidemiological alert. 2015 November Mexico Three cases of" exact="ZIKV" post="infection confirmed by PCR. 2015 November French Polynesia Retrospective"/>
  <result pre="America Honduras, French Guiana, and Martinique reported confirmed cases of" exact="ZIKV" post="infections. 2015 December Puerto Rico First confirmed case of"/>
  <result pre="ZIKV infections. 2015 December Puerto Rico First confirmed case of" exact="Zika" post="infection reported. 2016 Maldives Finnish national working in Maldivestested"/>
  <result pre="reported. 2016 Maldives Finnish national working in Maldivestested positive for" exact="Zika" post="after return to Finland. 2016 January Americas Guyana reported"/>
  <result pre="Americas Guyana reported the first PCR-confirmed case of locally acquired" exact="Zika" post="infection.Ecuador, Bolivia, Barbados, Haiti, Dominican Republic, Nicaragua, Curacao and"/>
  <result pre="Nicaragua, Curacao and Jamaica reported the first confirmed cases of" exact="Zika" post="infections.First case of Zika in St. Martin reported. 2016"/>
  <result pre="reported the first confirmed cases of Zika infections.First case of" exact="Zika" post="in St. Martin reported. 2016 January US Virgin Islands"/>
  <result pre="reported. 2016 January US Virgin Islands First confirmed case of" exact="Zika" post="in St. Croix reported. 2016 February Americas First confirmed"/>
  <result pre="St. Croix reported. 2016 February Americas First confirmed case of" exact="ZIKV" post="infection in Chile reported.First case of sexually transmitted Zika"/>
  <result pre="of ZIKV infection in Chile reported.First case of sexually transmitted" exact="Zika" post="infection in Texas, USA reported. 2016 Various countries Angola,"/>
  <result pre="Papua New Guinea, and other countries report first cases of" exact="ZIKV" post="infections. 2016 Singapore ZIKV infection reported. 2016/2017 India Three"/>
  <result pre="other countries report first cases of ZIKV infections. 2016 Singapore" exact="ZIKV" post="infection reported. 2016/2017 India Three cases of ZIKV infection"/>
  <result pre="2016 Singapore ZIKV infection reported. 2016/2017 India Three cases of" exact="ZIKV" post="infection reported in Ahmedabad. 2017 Singapore Several cases of"/>
  <result pre="reported in Ahmedabad. 2017 Singapore Several cases of locally transmitted" exact="ZIKV" post="confirmed. pharmaceuticals-12-00157-t004_Table 4Table 4 gR values of all sequences"/>
  <result pre="pharmaceuticals-12-00157-t004_Table 4Table 4 gR values of all sequences of the" exact="Zika" post="virus genome with 10,272 identified bases and selected hosts"/>
  <result pre="compounds led to twenty compounds that were found to reduce" exact="ZIKV" post="infection [93] NIH clinical library of compounds By screening"/>
  <result pre="ibuprofen, naproxen, acetaminophen, and lornoxicam, potently inhibited the entry of" exact="Zika" post="virus Env/HIV-1-pseudotyped viruses Inhibited replication of wild-type ZIKV both"/>
  <result pre="entry of Zika virus Env/HIV-1-pseudotyped viruses Inhibited replication of wild-type" exact="ZIKV" post="both in cell lines and in primary human fetal"/>
  <result pre="favorable selective index (SI) values. In a mouse model of" exact="ZIKV" post="infection (300 mg/kg/d), treatment with BCX4430 showed promising results."/>
 </snippets>
</snippetsTree>
